Latest News and Press Releases - GlobeNewswire
GlobeNewswire specializes in the distribution and delivery of press releases, financial disclosures and multimedia content to the media and general public.
www.globenewswire.comHere’s a concise update on Replimune Limited based on the latest available reporting.
- The U.S. FDA decision on RP1 (RP1 plus nivolumab) has dominated news cycles in 2025–2026. In July 2025 the FDA reportedly rejected the RP1 application, citing concerns about trial design and evidence, triggering a sharp stock drop and prompting discussions on next steps. This rejection followed earlier regulatory milestones, including a 2025 CRL and subsequent resubmission activity.[2][3][8]
- In early 2026, coverage highlighted an FDA action date of April 10, 2026 for a BLA resubmission, with the agency’s review discussions noting that the IGNYTE-3 data could potentially support approval, though market interpretation remained cautious given past regulatory hurdles.[1][2]
- Market and corporate updates in 2025–2026 also referenced financing and pipeline activity beyond RP1, including RP2 REVEAL for metastatic uveal melanoma and ongoing Phase 2 efforts, along with cash burn and balance sheet context as the company navigates regulatory uncertainty.[4][5][1]
If you’d like, I can pull the most current press releases or filings from Replimune’s investor relations site or the SEC to confirm the latest status and provide a brief timeline. I can also summarize the likely next steps for RP1 based on typical regulatory pathways (e.g., resubmission requirements, potential advisory committee hearings) with citations.